Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have been assigned an average rating of “Hold” from the eleven research firms that are presently covering the company ...
StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Tuesday ...
Hosted on MSN2mon
Immedica to buy Marinus Pharmaceuticals for $151mGlobal rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m. Marinus is a commercial-stage pharmaceutical company ...
Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and Exchange Commission.
Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and ...
MARINUS PHARMACEUTICALS ($MRNS) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback